Johnson & Johnson is ordered to pay $70m to boy who developed gynecomastiaBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i3846 (Published 11 July 2016) Cite this as: BMJ 2016;354:i3846
- Owen Dyer
Johnson & Johnson’s Janssen Pharmaceuticals division has been ordered by a Pennsylvania court to pay $70m (£54m; €63m) in damages to a young man who developed size 46DD breasts after taking the company’s antipsychotic drug risperidone (which it markets as Risperdal). Andrew Yount, 18, of Tennessee, began taking the drug when he was 5 years old, though it was not approved for use in children.
The jury found that Johnson & Johnson knew that the drug carried a risk of gynecomastia in men and boys but had “intentionally falsified, destroyed, or concealed records” to hide …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial